

# Jiwon Oh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/248458/publications.pdf>

Version: 2024-02-01

102  
papers

4,736  
citations

159525

30  
h-index

106281

65  
g-index

105  
all docs

105  
docs citations

105  
times ranked

6286  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of desire for pregnancy on decisions to escalate treatment in multiple sclerosis care: Differences between MS specialists and non-MS specialists. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103389.	0.9	6
2	Factors associated with treatment escalation among MS specialists and general neurologists: Results from an International cojoint study. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103404.	0.9	3
3	Clinical characteristics and outcomes of multiple sclerosis patients with COVID-19 in Toronto, Canada. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103509.	0.9	5
4	Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summary. <i>Neurodegenerative Disease Management</i> , 2022, 12, 1-7.	1.2	2
5	Assessment of Natural Language Processing Methods for Ascertaining the Expanded Disability Status Scale Score From the Electronic Health Records of Patients With Multiple Sclerosis: Algorithm Development and Validation Study. <i>JMIR Medical Informatics</i> , 2022, 10, e25157.	1.3	7
6	Productivity loss among people with early multiple sclerosis: A Canadian study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1414-1423.	1.4	12
7	Multisite MRI reproducibility of lateral ventricular volume using the NAIMS cooperative pilot dataset. <i>Journal of Neuroimaging</i> , 2022, 32, 910-919.	1.0	2
8	021â€¦ Determinants of natalizumab-associated PML outcomes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A20.1-A20.	0.9	0
9	Peripartum disease activity in moderately and severely disabled women with multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022, 8, 205521732211049.	0.5	2
10	Emerging therapies to target CNS pathophysiology in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2022, 18, 466-475.	4.9	25
11	Five-year longitudinal changes in quantitative spinal cord MRI in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 549-558.	1.4	6
12	Clinical and MRI characteristics of multiple sclerosis in patients of Middle Eastern and North African ancestry residing in Ontario, Canada. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1027-1036.	1.4	6
13	Efficacy and Safety of Teriflunomide in Multiple Sclerosis across Age Groups: Analysis from Pooled Pivotal and Real-world Studies. <i>Journal of Central Nervous System Disease</i> , 2021, 13, 117957352110287.	0.7	5
14	Central vein sign: A diagnostic biomarker in multiple sclerosis (CAVS-MS) study protocol for a prospective multicenter trial. <i>NeuroImage: Clinical</i> , 2021, 32, 102834.	1.4	23
15	Cognitive impairment, the central vein sign, and paramagnetic rim lesions in RIS. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2199-2208.	1.4	25
16	Deep grey matter injury in multiple sclerosis: a NAIMS consensus statement. <i>Brain</i> , 2021, 144, 1974-1984.	3.7	31
17	Vitamin D as disease-modifying therapy for multiple sclerosis?. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 691-693.	1.3	3
18	Challenges in multiple sclerosis care: Results from an international mixed-methods study. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 50, 102854.	0.9	17

#	ARTICLE	IF	CITATIONS
19	The potential of serum neurofilament as biomarker for multiple sclerosis. <i>Brain</i> , 2021, 144, 2954-2963.	3.7	98
20	Ozanimod for the treatment of relapsing forms of multiple sclerosis. <i>Neurodegenerative Disease Management</i> , 2021, 11, 207-220.	1.2	3
21	Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110242.	0.5	4
22	Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement. <i>Journal of Neuroimmunology</i> , 2021, 357, 577627.	1.1	33
23	2021 MAGNIMSâ€“CMSCâ€“NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. <i>Lancet Neurology</i> , The, 2021, 20, 653-670.	4.9	302
24	A window into the future? MRI for evaluation of neuromyelitis optica spectrum disorder throughout the disease course. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110143.	1.5	16
25	Manifestations and impact of the COVIDâ€“19 pandemic in neuroinflammatory diseases. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 918-928.	1.7	21
26	The Canadian prospective cohort study to understand progression in multiple sclerosis (CanProCo): rationale, aims, and study design. <i>BMC Neurology</i> , 2021, 21, 418.	0.8	5
27	Intensity warping for multisite MRI harmonization. <i>NeuroImage</i> , 2020, 223, 117242.	2.1	34
28	Mystery Case: Migraine, hearing loss, and blurred vision in a young woman. <i>Neurology</i> , 2020, 95, e2945-e2950.	1.5	0
29	ICU Service Transitions of Care and the Effect on Patient Outcomes. , 2020, , .		0
30	Imaging Mechanisms of Disease Progression in Multiple Sclerosis: Beyond Brain Atrophy. <i>Journal of Neuroimaging</i> , 2020, 30, 251-266.	1.0	24
31	Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations. <i>Canadian Journal of Neurological Sciences</i> , 2020, 47, 437-455.	0.3	63
32	Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 43, 102146.	0.9	23
33	Detection of central vein should be part of MS diagnostic criteria â€“ Commentary. <i>Multiple Sclerosis Journal</i> , 2020, 26, 409-410.	1.4	1
34	Paramagnetic Rim Sign in Radiologically Isolated Syndrome. <i>JAMA Neurology</i> , 2020, 77, 653.	4.5	40
35	New imaging approaches for precision diagnosis and disease staging of MS?. <i>Multiple Sclerosis Journal</i> , 2020, 26, 568-575.	1.4	9
36	Effect of an Educational Intervention on Therapeutic Inertia in Neurologists With Expertise in Multiple Sclerosis. <i>JAMA Network Open</i> , 2020, 3, e2022227.	2.8	9

#	ARTICLE	IF	CITATIONS
37	A Disentangled Latent Space for Cross-Site MRI Harmonization. Lecture Notes in Computer Science, 2020, , 720-729.	1.0	22
38	Short-term effects of air pollution on hospital admission for heart failure among older adults: a time-series study. ISEE Conference Abstracts, 2020, 2020, .	0.0	0
39	Indoor and outdoor particulate matter and serum levels of lead and cadmium among Korean housewives: a panel study. ISEE Conference Abstracts, 2020, 2020, .	0.0	0
40	DeepHarmony: A deep learning approach to contrast harmonization across scanner changes. Magnetic Resonance Imaging, 2019, 64, 160-170.	1.0	150
41	Comparison of Physician Therapeutic Inertia for Management of Patients With Multiple Sclerosis in Canada, Argentina, Chile, and Spain. JAMA Network Open, 2019, 2, e197093.	2.8	18
42	Head-to-head drug comparisons in multiple sclerosis. Neurology, 2019, 93, 793-809.	1.5	20
43	Multisite reliability and repeatability of an advanced brain MRI protocol. Journal of Magnetic Resonance Imaging, 2019, 50, 878-888.	1.9	27
44	Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study. Multiple Sclerosis and Related Disorders, 2019, 33, 131-138.	0.9	15
45	Emotional expressions associated with therapeutic inertia in multiple sclerosis care. Multiple Sclerosis and Related Disorders, 2019, 34, 17-28.	0.9	3
46	Implementing the 2017 McDonald criteria for the diagnosis of multiple sclerosis. Nature Reviews Neurology, 2019, 15, 441-445.	4.9	18
47	The Central Vein Sign in Radiologically Isolated Syndrome. American Journal of Neuroradiology, 2019, 40, 776-783.	1.2	41
48	Management strategies for female patients of reproductive potential with multiple sclerosis: An evidence-based review. Multiple Sclerosis and Related Disorders, 2019, 32, 54-63.	0.9	37
49	Imaging outcome measures of neuroprotection and repair in MS. Neurology, 2019, 92, 519-533.	1.5	53
50	Diagnosis and management of secondary-progressive multiple sclerosis: time for change. Neurodegenerative Disease Management, 2019, 9, 301-317.	1.2	22
51	An Automated Statistical Technique for Counting Distinct Multiple Sclerosis Lesions. American Journal of Neuroradiology, 2018, 39, 626-633.	1.2	24
52	Quantitative spinal cord MRI in radiologically isolated syndrome. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e436.	3.1	39
53	Gradient nonlinearity effects on upper cervical spinal cord area measurement from 3D T <sub>1</sub> -weighted brain MRI acquisitions. Magnetic Resonance in Medicine, 2018, 79, 1595-1601.	1.9	27
54	Spinal Cord MRI in Multiple Sclerosis. Neurologic Clinics, 2018, 36, 35-57.	0.8	17

#	ARTICLE	IF	CITATIONS
55	The NAIMS cooperative pilot project: Design, implementation and future directions. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1770-1772.	1.4	12
56	Multiple sclerosis: clinical aspects. <i>Current Opinion in Neurology</i> , 2018, 31, 752-759.	1.8	324
57	Brain and retinal atrophy in African-Americans versus Caucasian-Americans with multiple sclerosis: a longitudinal study. <i>Brain</i> , 2018, 141, 3115-3129.	3.7	67
58	Therapeutic Inertia in Multiple Sclerosis Care: A Study of Canadian Neurologists. <i>Frontiers in Neurology</i> , 2018, 9, 781.	1.1	16
59	Deep Harmonization of Inconsistent MR Data for Consistent Volume Segmentation. <i>Lecture Notes in Computer Science</i> , 2018, , 20-30.	1.0	7
60	Toward a Shared-Care Model of Relapsing-Remitting Multiple Sclerosis: Role of the Primary Care Practitioner. <i>Canadian Journal of Neurological Sciences</i> , 2018, 45, 304-312.	0.3	7
61	Usability of an Educational Intervention to Overcome Therapeutic Inertia in Multiple Sclerosis Care. <i>Frontiers in Neurology</i> , 2018, 9, 522.	1.1	3
62	Spinal Cord Atrophy in Multiple Sclerosis: A Systematic Review and Meta-Analysis. <i>Journal of Neuroimaging</i> , 2018, 28, 556-586.	1.0	72
63	Imaging Markers for Monitoring Disease Activity in Multiple Sclerosis. <i>Current Treatment Options in Neurology</i> , 2017, 19, 18.	0.7	6
64	Clinical pitfall: false-positive aquaporin-4 IgG leading to misdiagnosis of neuromyelitis optica spectrum disorder in patient with spinal arteriovenous fistula. <i>Spinal Cord Series and Cases</i> , 2017, 3, 17030.	0.3	4
65	Response to 'Foix-Alajouanine is another differential diagnosis in longitudinal myelitis thought to be a case of multiple sclerosis or neuromyelitis optica'. <i>Spinal Cord Series and Cases</i> , 2017, 3, 17059.	0.3	1
66	Volumetric Analysis from a Harmonized Multisite Brain MRI Study of a Single Subject with Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2017, 38, 1501-1509.	1.2	95
67	1127â€¦Pregnancy outcomes in alemtuzumab trials and registry design. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, A3.1-A3.	0.9	0
68	Magnetic susceptibility contrast variations in multiple sclerosis lesions. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 43, 463-473.	1.9	79
69	PREGNANCY OUTCOMES IN ALEMTUZUMAB-TREATED PATIENTS WITH RRMS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, e1.63-e1.	0.9	4
70	OP0074â€¦Ebselen Is A Potential Anti-Osteoporosis Agent by Suppressing Receptor Activator of Nuclear Factor Kappa-B Ligand-Induced Osteoclast Differentiation In Vitro and Lipopolysaccharide-Induced Inflammatory Bone Destruction In Vivo. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 82.3-83.	0.5	0
71	The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. <i>Nature Reviews Neurology</i> , 2016, 12, 714-722.	4.9	274
72	Comparison of Sagittal FSE T2, STIR, and T1-Weighted Phase-Sensitive Inversion Recovery in the Detection of Spinal Cord Lesions in MS at 3T. <i>American Journal of Neuroradiology</i> , 2016, 37, 970-975.	1.2	32

#	ARTICLE	IF	CITATIONS
73	Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2016, 37, 394-401.	1.2	277
74	A NOVEL SEARCH BUILDER TO EXPEDITE SEARCH STRATEGIES FOR SYSTEMATIC REVIEWS. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 51-53.	0.2	11
75	Optical coherence tomography reflects brain atrophy in multiple sclerosis: A four-year study. <i>Annals of Neurology</i> , 2015, 78, 801-813.	2.8	304
76	Novel and imminently emerging treatments in relapsing-remitting multiple sclerosis. <i>Current Opinion in Neurology</i> , 2015, 28, 230-236.	1.8	7
77	Established disease-modifying treatments in relapsing-remitting multiple sclerosis. <i>Current Opinion in Neurology</i> , 2015, 28, 220-229.	1.8	29
78	Relationships between quantitative spinal cord MRI and retinal layers in multiple sclerosis. <i>Neurology</i> , 2015, 84, 720-728.	1.5	52
79	Thalamic lesions in multiple sclerosis by 7T MRI: Clinical implications and relationship to cortical pathology. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1139-1150.	1.4	49
80	Progress in MS classification, mechanisms and treatment. <i>Nature Reviews Neurology</i> , 2015, 11, 76-78.	4.9	19
81	Association of Cortical Lesion Burden on 7-T Magnetic Resonance Imaging With Cognition and Disability in Multiple Sclerosis. <i>JAMA Neurology</i> , 2015, 72, 1004.	4.5	140
82	Canadian Expert Panel Recommendations for MRI Use in MS Diagnosis and Monitoring. <i>Canadian Journal of Neurological Sciences</i> , 2015, 42, 159-167.	0.3	20
83	Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis. <i>Neurology</i> , 2014, 82, 984-988.	1.5	22
84	Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects. <i>Therapeutic Advances in Neurological Disorders</i> , 2014, 7, 239-252.	1.5	33
85	Restoring Systemic GDF11 Levels Reverses Age-Related Dysfunction in Mouse Skeletal Muscle. <i>Science</i> , 2014, 344, 649-652.	6.0	706
86	Spinal Cord Normalization in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2014, 24, 577-584.	1.0	35
87	Disease-modifying agents in multiple sclerosis. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 122, 465-501.	1.0	10
88	Safety, Tolerability, and Efficacy of Oral Therapies for Relapsing-Remitting Multiple Sclerosis. <i>CNS Drugs</i> , 2013, 27, 591-609.	2.7	21
89	Emerging injectable therapies for multiple sclerosis. <i>Lancet Neurology</i> , The, 2013, 12, 1115-1126.	4.9	31
90	Automatic magnetic resonance spinal cord segmentation with topology constraints for variable fields of view. <i>NeuroImage</i> , 2013, 83, 1051-1062.	2.1	63

#	ARTICLE	IF	CITATIONS
91	Relationships Between Retinal Axonal and Neuronal Measures and Global Central Nervous System Pathology in Multiple Sclerosis. <i>JAMA Neurology</i> , 2013, 70, 34.	4.5	197
92	Teriflunomide. <i>Neurology: Clinical Practice</i> , 2013, 3, 254-260.	0.8	11
93	Multiparametric MRI correlates of sensorimotor function in the spinal cord in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 427-435.	1.4	68
94	Spinal cord quantitative MRI discriminates between disability levels in multiple sclerosis. <i>Neurology</i> , 2013, 80, 540-547.	1.5	72
95	In Vivo Demonstration of Homonymous Hemimacular Loss of Retinal Ganglion Cells Due to a Thalamic Lesion Using Optical Coherence Tomography. <i>JAMA Neurology</i> , 2013, 70, 410.	4.5	5
96	Teriflunomide for the Treatment of Multiple Sclerosis. <i>Seminars in Neurology</i> , 2013, 33, 307-308.	0.5	0
97	Teriflunomide for the Treatment of Multiple Sclerosis. <i>Seminars in Neurology</i> , 2013, 33, 045-055.	0.5	14
98	An update of teriflunomide for treatment of multiple sclerosis. <i>Therapeutics and Clinical Risk Management</i> , 2013, 9, 177.	0.9	28
99	Neuromyelitis Optica: An Antibody-Mediated Disorder of the Central Nervous System. <i>Neurology Research International</i> , 2012, 2012, 1-13.	0.5	64
100	Progressive Cognitive Decline in a Patient With Isolated Chronic Neurosarcoidosis. <i>Neurologist</i> , 2010, 16, 50-53.	0.4	8
101	Liddle's syndrome: a report in a middle-aged woman. <i>Yonsei Medical Journal</i> , 2000, 41, 276.	0.9	8
102	Severe, acute meningeal irritative reaction after epidural blood patch. <i>Anesthesia and Analgesia</i> , 1998, 87, 1139-40.	1.1	30